Glioblastomas are high-grade brain tumours with a poor prognosis and, currently, few available therapeutic options. This lack of effective treatments has been linked to diverse factors, including target selection, tumour heterogeneity and poor penetrance of therapeutic agents through the blood–brain barrier and into tumours. Therapies using monoclonal antibodies, alone or linked to cytotoxic payloads, have proved beneficial for patients with different solid tumours; these approaches are currently being explored in patients with glioblastoma. In this Review, we summarise clinical data regarding antibody–drug conjugates (ADCs) against a variety of targets in glioblastoma, and compare the efficacy and toxicity of targeting EGFR with ADCs versus naked antibodies in order to illustrate key aspects of the use of ADCs in this malignancy. Finally, we discuss the complex challenges related to the biology and mutational changes of glioblastoma that can affect the use of ADC-based therapies in patients with this disease, and highlight potential strategies to improve efficacy.

胶质母细胞瘤是高级脑肿瘤，预后较差，目前尚无可用的治疗选择。缺乏有效治疗的原因与多种因素有关，包括靶标选择，肿瘤异质性和治疗剂透过血脑屏障进入肿瘤的渗透性差。事实证明，使用单克隆抗体单独或与细胞毒性有效载荷结合使用的疗法，对于具有不同实体瘤的患者是有益的。目前正在胶质母细胞瘤患者中探索这些方法。在本综述中，我们总结了针对胶质母细胞瘤中多种靶标的抗体-药物偶联物（ADC）的临床数据，并比较了将ADC靶向EGFR与裸抗体靶向的疗效和毒性，以阐明在ADC中使用ADC的关键方面。这种恶性肿瘤。最后，